Immunovant, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Shareholder voteSep 3 →Insiders1 insider bought $350.0M in 1 open-market buy. 10 insiders sold $11.6M, 7 of 36 sales on a 10b5-1 plan.→HoldersFMR 7.8%Deep Track Capital 4.5%BlackRock 3.5%→PeersClosest companies: ROIV, VERA, VRDN→
From the filings
Figures
- Net income
- −$538.2Mlast 12 months
- Operating cash flow
- −$414.3Mlast 12 months
- Cash and equivalents
- $797.8Mat the last balance sheet
- Shares outstanding
- 206.3M shareson issue